Sunshine Lake Pharma Co (6887) H2 2025 earnings summary

Executive summary

• Revenue rose 19.81% year-over-year to RMB4,815.07 million, driven by strong demand for oseltamivir phosphate and robust performance across business lines.

• Net profit reached RMB270.03 million, a significant turnaround from a RMB24.80 million profit in 2024, with profit attributable to equity shareholders at RMB272.44 million versus a loss last year.

• Gross profit increased 20.49% to RMB3,685.40 million, reflecting higher sales volumes, especially in anti-infective drugs.

• No final dividend was declared for 2025.

Financial highlights

• Operating profit rose to RMB669.72 million from RMB380.55 million year-over-year.

• EBITDA (profit before interest, tax, depreciation, and amortization) increased to RMB1,125.21 million, up RMB332.84 million from 2024.

• Basic and diluted EPS were RMB0.56 and RMB0.55, respectively.

• Gearing ratio increased to 105.27% (from 100.35%), and quick ratio decreased to 0.64 (from 0.88).

• Net current liabilities stood at RMB1,387.18 million, down from net current assets of RMB164.51 million in 2024.

Outlook and guidance

• Strategic focus remains on innovation, internationalization, and expanding the R&D pipeline, with continued investment in AI-driven drug discovery and commercialization.

• Plans to enhance operational efficiency, optimize production, and strengthen global distribution and brand presence.